EyePoint Pharmaceuticals' Stock Drops Over 80% After Late-Stage Trial Failure
EyePoint Pharmaceuticals (EYPT:NASDAQ) experienced a significant decline in premarket trading, losing over 80%, following the failure of its lead drug candidate Duravyu in a late-stage clinical trial. The study compared Duravyu to Regeneron's Eylea (2 mg aflibercept), which is widely used for treating eye diseases and has strong market dominance. The disappointing results have raised concerns about EyePoint’s future prospects, particularly as the company had been counting on Duravyu's success in this trial. The setback highlights risks associated with late-stage drug development and could impact investor confidence across biotech firms working on similar therapies.
